January 11, 2017
Astellas Pharma said on January 10 that it has exercised its right to terminate an accord with Japanese biotech startup UMN Pharma for the joint development of cell culture-based influenza vaccines, ASP7374 and ASP7373, which it originally planned to exclusively...read more